US › Healthcare

Collplant Biotechnologies Ltd (CLGN)

US · Healthcare · Biotechnology

$0.29-9.81%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$73,000

Revenue YoY

-96.4%

Net profit

$-3.1M

Profit YoY

-113.3%

EPS

$-0.23

EPS estimate

$-0.13

Net margin

-4,242.5%

EPS came in at -0.23 against a street estimate of -0.13 — a miss of 72.5%.

Key statistics

Market cap

$6.0M

Forward P/E

80.0

P/B

1.06

Book value

$0.34

EPS (TTM)

$-1.04

52-week high

$3.23

52-week low

$0.27

50-day MA

$0.36

200-day MA

$1.01

Beta

0.68

Analyst view

Analysts rate Collplant Biotechnologies Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.12.

Shareholding

Insiders

29.79%

Institutions

9.18%

Largest institutional holders

Fund	Stake
Parallel Advisors, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Collplant Biotechnologies Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.